Purple Biotech announces their novel CAPTN-3 tri-specific antibody platform at EACR 2025. The company focuses on developing first-in-class therapies to overcome tumor immune evasion and drug resistance. Their oncology pipeline includes CM24, a humanized monoclonal antibody that blocks CEACAM1 to target multiple cancer indications. NT219, a dual inhibitor small molecule, demonstrated anti-tumor activity in a […]
